Payment overview · 2025
General Payments
$19.05
1 reported records · 1 companies
Healthcare provider profile · identity verified
Jeffrey Bruce Studebaker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKVILLE, OH · NPI 1356427140
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Bruce Studebaker, M.D. received $19.05 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.05 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $19.05 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 164 |
| Lisinopril | Lisinopril | 386 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 372 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 324 | 90 |
| Gabapentin | Gabapentin | 284 | 61 |
| Metformin Hcl | Metformin Hcl | 262 | 85 |
| Omeprazole | Omeprazole | 228 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 58 |
| Eliquis | Apixaban | 183 | 33 |
| Chlorthalidone | Chlorthalidone | 182 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 28 |
| Allopurinol | Allopurinol | 131 | 28 |
| Furosemide | Furosemide | 128 | 31 |
| Valsartan | Valsartan | 125 | 36 |
| Losartan Potassium | Losartan Potassium | 117 | 29 |
| Simvastatin | Simvastatin | 113 | 34 |
| Mirtazapine | Mirtazapine | 111 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 26 |
| Naproxen | Naproxen | 100 | 26 |
| Prednisone | Prednisone | 97 | 61 |
| Glimepiride | Glimepiride | 96 | 21 |
| Buspirone Hcl | Buspirone Hcl | 92 | 19 |
| Trazodone Hcl | Trazodone Hcl | 92 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 23 |
| Glipizide | Glipizide | 81 | 20 |
| Sertraline Hcl | Sertraline Hcl | 81 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 31 |
| Spironolactone | Spironolactone | 74 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 17 |
| Famotidine | Famotidine | 70 | 15 |
| Synthroid | Levothyroxine Sodium | 70 | 22 |
| Alendronate Sodium | Alendronate Sodium | 66 | 18 |
| Donepezil Hcl | Donepezil Hcl | 66 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 18 |
| Tramadol Hcl | Tramadol Hcl | 64 | 21 |
| Atenolol | Atenolol | 62 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 43 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 41 |
| Potassium Chloride | Potassium Chloride | 56 | 18 |
| Propranolol Hcl | Propranolol Hcl | 56 | 14 |
| Jardiance | Empagliflozin | 55 | 13 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Trulicity | Dulaglutide | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 13 |
| Methocarbamol | Methocarbamol | 49 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Ondansetron Odt | Ondansetron | 44 | 17 |
| Glipizide Er | Glipizide | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 11 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Meloxicam | Meloxicam | 35 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 24 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | 11 |
| Klor-Con M20 | Potassium Chloride | 32 | suppressed |
| Repaglinide | Repaglinide | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | 11 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $19.05 · 1 records | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error